AEOLUS PHARMACEUTICALS, INC. (OTCMKTS:AOLS) Files An 8-K Other Events

AEOLUS PHARMACEUTICALS, INC. (OTCMKTS:AOLS) Files An 8-K Other Events
Item 8.01. Other Events

Aeolus Pharmaceuticals, Inc. (the “Company”) received notice from the Assistant Secretary for Preparedness and Response (“ASPR”) that the Biomedical Advanced Research and Development Authority (“BARDA”) elected not to exercise additional options under its contract entitled: “Advanced Development of AEOL10150 as a Medical Countermeasure for Pulmonary Injury Associated with ARS and DEARE.” The notification was sent to Aeolus in response to an “In-Process Review” (“IPR”) meeting held with BARDA on February 2, 2017.


About AEOLUS PHARMACEUTICALS, INC. (OTCMKTS:AOLS)

Aeolus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on developing a platform of compounds for use in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. As of September 30, 2016, the Company’s platform consisted of approximately 180 compounds licensed from the University of Colorado (UC), Duke University (Duke) and National Jewish Health (NJH). The Company’s lead compound is AEOL 10150, which is being developed as a medical countermeasure (MCM) against the pulmonary sub-syndrome of acute radiation syndrome (Pulmonary Acute Radiation Syndrome or Lung-ARS) and the delayed effects of acute radiation exposure (DEARE). Its other product is AEOL 11114 and AEOL 20415. AEOL 10150 is indicated for the treatment of radiation oncology and idiopathic pulmonary fibrosis. AEOL 11114 is indicated for the treatment of Parkinson’s disease and epilepsy. AEOL 20415 is an orally-available, anti-infective compound.

AEOLUS PHARMACEUTICALS, INC. (OTCMKTS:AOLS) Recent Trading Information

AEOLUS PHARMACEUTICALS, INC. (OTCMKTS:AOLS) closed its last trading session up +0.0100 at 0.0970 with shares trading hands.

An ad to help with our costs